Objective

The Gram-negative bacterial pathogen Burkholderia pseudomallei is the etiological cause of melioidosis. As of 2018 there were 165,000 global estimated annual morbidities, including 89,000 deaths, mostly in Southeast Asia where the disease is endemic [1]. B. pseudomallei is considered a high priority biohazard due to its prevalence in soil and water, high virulence associated with inhalation exposure, low infective dose, high mortality rates, native resistance to a wide range of antibiotics, and paucity of an efficient licensed vaccine [2,3,4]. Melioidosis symptoms are nonspecific, thus hindering identification of the disease, which may inadvertently be diagnosed as tuberculosis or a common form of pneumonia [1, 5, 6]. The B. pseudomallei genome is highly plastic, resulting in significant sequence variability amongst strains [7]. Melioidosis cases are sporadically identified in nonendemic areas, usually associated with travelers or transport of goods from endemic regions. Due to extensive intercontinental traveling and the anticipated climate change-associated alterations of the soil bacterial flora, there is an increasing concern for inadvertent establishment of novel endemic areas which may expand the global burden of melioidosis. Rapid diagnosis, isolation and characterization of B. pseudomallei isolates is therefore of utmost importance, in particular in non-endemic locations.

Two Israelis returning from Southeast Asia, one from Thailand and the other from India, were hospitalized in different medical centers due to fulminant symptoms reminiscent of acute pneumonia, subsequently diagnosed as travel-related melioidosis. The objective of the study documented in this brief data note, was genetic identification of the etiologic pathogen isolated from these clinical cases, and analysis of the respective bacterial genomes for taxonomic typing and primary determination of their genetic characteristics.

Data description

We report the draft genome of two novel clinical B. pseudomallei strains denoted MWH2021 and MST2022 isolated from melioidosis cases diagnosed in Israel, associated with travelers from India and Thailand, respectively.

Previously, three additional clinical isolates of melioidosis were documented in Israel, from Thailand [8], Eritrea [9] and India [10, 11]. The strains described in the current report were acknowledged as B. pseudomallei by the Vitek KL2 bacterial identification system and MALDI-TOF (Bruker) mass spectrometric analysis and confirmed by PCR analysis [12]. Virulence analysis of the strains was performed in the melioidosis murine model [13, 14]. MWH2021 strain exhibited an intranasal (IN) Lethal Dose 50% (LD50; more than 30 days survival of mice inoculated with increasing doses, calculated by linear regression using the GraphPad Prism V5 software [10, 13, 15]) of 126 CFU and 950 CFU in the BALB/c and C57BL/6J strains of mice, respectively. LD50 of strain MST2022 was 13 CFU and 83 CFU (BALB/c and C57BL/6J mice, respectively). Of note, Balb/c serves for modeling the acute form of melioidosis while C57BL/6J recapitulates the chronic form. The data indicate that both novel clinical isolates belong to the group of highly virulent strains [16].

Genome sequencing of B. pseudomallei MWH2021 and MST2022 isolates employed purified chromosomal DNA isolated from BHI-agar colonies, which served for generation of genomic libraries (Nextera XT kit, Illumina). Sequencing of both strains was performed on Miseq Instrument (Illumina), generating short-read sequences. Long-read sequencing using Oxford Nanopore Technologies, produced additional data sets which enabled improved assembly [13].

The genomic sequences of the two novel strains were deposited to the NCBI database [17,18,19,20]. The data deposited in the various public databases as well as supplementary material pertaining to this data note are detailed in Table 1. To determine the phylogenetic relation of the novel strains to other B. pseudomallei strains. A total of 131 complete genome sequences were downloaded from NCBI [21]. Core genome alignment and phylogeny of the strains relative to the reference genome strain Mahidol-1106a (accession number GCF_000756125.1) were performed using the Parsnp software, v1.2 [22]. The resulting phylogenetic tree, depicted in the Supplementary Fig. 1 [23] was shaped with the iTOL: interactive tree of life platform [24]. This analysis established that the novel MWH2021 strain is adjacent in the phylogenetic clustering to strain MAA2018 [10, 11], in line with their common geographic origin (India). The two isolates differ by 8,879 and 7,408 SNPs on chromosome 1 and 2, respectively, clearly indicating that in spite of their phylogenetic vicinity they represent distinct strains. In general, as expected, the analysis established a strong correlation between genomic DNA sequence similarities of various strains and their respective geographical origin (see Supplementary Fig. 1).

The genomes of the novel strains, as well as those of the three additional strains BP1, BP2 and MAA2018 previously isolated and documented in Israel from cases of melioidosis [8,9,10,11, 13], were interrogated for the presence of 36 genes encoding for potential B. pseudomallei virulence factors [1, 3]. The results summarized in Supplementary Data 2 [14], show that all these genes are present in the genome of the novel strain MWH2021. In this regard, this strain does not differ from the previously documented strain of Indian origin, in line with their phylogenetic proximity. Three genes (chbP, boaB and boaA) were not identified in the genome of the novel strain MST2022. While these genes encode for factors believed to be involved in the virulence of the bacteria [25,26,27], their absence did not correlate with decreased virulence of the MST2022 [14], in accordance with the notion that pathology of melioidosis involves the activity of numerous bacterial factors whose individual contribution to virulence is difficult to assess.

Table 1 Overview of data files/data sets
Full size table

Limitation

Bioinformatic DNA similarity analysis of the genomic sequences of the two novel clinical isolates, for determining their phylogenetic relation to other B. pseudomallei strains [23, 28], was conducted using 131 complete B. pseudomallei genomes present in the NCBI databank (as of June 2023). It is conceivable that conducting the analysis by comparison to all available B. pseudomallei genomes (not only complete ones), may have provided a more comprehensive phylogenetic profile.

The bioinformatics screen of the sequences for potential virulence factors did not include inspection of the possible point mutations or indels (insertions/deletions) but only presence or absence of the respective orthologous genes, therefore the study cannot attest for their level of expression.